Last updated: 2026-09-15 03:05:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Enveric Biosciences, Inc. (ENVB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,49, with a market capitalisation of $6,36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,17 to $13,25. This page covers its latest market performance, valuation, price trends and company information.
$6,36M | |
$1,42 | |
$63 000,00 | |
$1,17 | |
$1,42 | |
99,61K | |
147,38K | |
-- | |
$13,25 | |
$1,17 | |
-- | |
-- |
Enveric Biosciences, Inc. (ENVB) last closed at $1,42 as of 2026-09-14 23:59:00, unchanged from the previous close of $1,42.
During the latest regular trading session, ENVB traded between $1,17 and $63 000,00, with a volume of 99,61K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Enveric Biosciences, Inc. (ENVB) moved from $1,44 to $1,49, representing a gain of 3,47% ($0,05).
The stock traded between $1,36 and $1,52 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 36,08 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2,6%
ENVB is currently trading at $1,49, placing it 2,6% of the way from its 52-week low of $1,17 to its 52-week high of $13,25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Enveric Biosciences, Inc. (ENVB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.